Payment overview · 2025
General Payments
$783.29
39 reported records · 13 companies
Healthcare provider profile · identity verified
Matthew Wayne Murray, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · MOSS POINT, MS · NPI 1124389366
Verified facts
What the public records show
CMS Open Payments records show Matthew Wayne Murray, M.D. received $783.29 in general payments during 2025 across 39 reported records.
Abbott Laboratories accounted for 14.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 24 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Mounjaro, Ozempic, Shingrix, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 35 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 168 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 101 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 31 claims for Symbicort by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SHINGRIX as an associated drug or biological on 43515 records involving 26794 distinct recipient NPIs. Public Medicare Part D data also shows 41 claims for Shingrix by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 30 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 100 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 61 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 59 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 137 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Wegovy as an associated drug or biological on 183056 records involving 75256 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Wegovy by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 77 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Abbott Laboratories | Unresolved — no canonical attribution shown | $112.63 | 14.4% | 6 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $107.49 | 13.7% | 5 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $88.01 | 11.2% | 4 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $76.36 | 9.8% | 5 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $74.48 | 9.5% | 3 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $64.61 | 8.2% | 3 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $62.34 | 8.0% | 3 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $61.46 | 7.8% | 3 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $39.49 | 5.0% | 2 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $36.86 | 4.7% | 2 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $26.51 | 3.4% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $18.94 | 2.4% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $14.11 | 1.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $783.29 | 39 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| FREESTYLE LIBRE Normalized: freestyle libre |
Device | Abbott Laboratories | $112.63 | 6 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $107.49 | 5 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $88.01 | 4 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC | $64.61 | 3 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $50.97 | 2 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $46.25 | 3 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $44.98 | 2 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $40.72 | 2 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $39.49 | 2 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $33.41 | 2 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $30.11 | 2 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $28.93 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $28.93 | 1 | 2025 |
Source payment records
|
|||||
| GVOKE HYPOPEN Normalized: gvoke hypopen |
Drug | Xeris Pharmaceuticals, Inc. | $26.51 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $24.14 | 1 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $22.52 | 1 | 2025 |
Source payment records
|
|||||
| PROLIA Normalized: prolia |
Biological | Amgen Inc. | $22.52 | 1 | 2025 |
Source payment records
|
|||||
| KISUNLA Normalized: kisunla |
Drug | Lilly USA, LLC | $20.74 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $18.94 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $14.34 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $14.34 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $14.11 | 1 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $14.11 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $13.90 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 61 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 137 | exact normalized | Medicare Part D |
| SHINGRIX shingrix |
2025 | Shingrix | 2024 | 41 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 30 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
35 | 15 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
168 | 47 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
101 | 23 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
31 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | SHINGRIX open payments reported associated product |
CMS Open Payments — General Payments 43515 supporting records · 26794 recipient NPIs · example record 1190332452 |
Shingrix · 2024 Exact normalized brand match · 1 Part D row |
41 | 32 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
30 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
100 | 31 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
61 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
59 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
137 | 28 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Wegovy open payments reported associated product |
CMS Open Payments — General Payments 183056 supporting records · 75256 recipient NPIs · example record 1188130070 |
Wegovy · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
77 | 19 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
22 | 22 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 1420 | 387 |
| Amlodipine Besylate | Amlodipine Besylate | 1379 | 390 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 1039 | 301 |
| Levothyroxine Sodium | Levothyroxine Sodium | 841 | 207 |
| Omeprazole | Omeprazole | 781 | 238 |
| Metformin Hcl | Metformin Hcl | 643 | 196 |
| Losartan Potassium | Losartan Potassium | 640 | 172 |
| Hydrochlorothiazide | Hydrochlorothiazide | 507 | 151 |
| Gabapentin | Gabapentin | 478 | 171 |
| Lisinopril | Lisinopril | 444 | 125 |
| Fluticasone Propionate | Fluticasone Propionate | 430 | 180 |
| Pantoprazole Sodium | Pantoprazole Sodium | 418 | 122 |
| Tamsulosin Hcl | Tamsulosin Hcl | 399 | 128 |
| Metoprolol Succinate | Metoprolol Succinate | 390 | 114 |
| Meloxicam | Meloxicam | 379 | 144 |
| Escitalopram Oxalate | Escitalopram Oxalate | 345 | 103 |
| Furosemide | Furosemide | 335 | 130 |
| Glipizide | Glipizide | 313 | 91 |
| Trazodone Hcl | Trazodone Hcl | 271 | 94 |
| Ezetimibe | Ezetimibe | 253 | 77 |
| Carvedilol | Carvedilol | 251 | 71 |
| Tizanidine Hcl | Tizanidine Hcl | 238 | 103 |
| Duloxetine Hcl | Duloxetine Hcl | 235 | 75 |
| Potassium Chloride | Potassium Chloride | 231 | 85 |
| Bupropion Xl | Bupropion Hcl | 219 | 65 |
| Allopurinol | Allopurinol | 212 | 64 |
| Pioglitazone Hcl | Pioglitazone Hcl | 206 | 66 |
| Pravastatin Sodium | Pravastatin Sodium | 204 | 63 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 186 | 54 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 185 | 54 |
| Montelukast Sodium | Montelukast Sodium | 184 | 61 |
| Valsartan | Valsartan | 175 | 69 |
| Buspirone Hcl | Buspirone Hcl | 173 | 59 |
| Clopidogrel | Clopidogrel Bisulfate | 169 | 49 |
| Synthroid | Levothyroxine Sodium | 168 | 47 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 159 | 51 |
| Metoprolol Tartrate | Metoprolol Tartrate | 149 | 42 |
| Sertraline Hcl | Sertraline Hcl | 142 | 39 |
| Ozempic | Semaglutide | 137 | 28 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 130 | 92 |
| Simvastatin | Simvastatin | 128 | 34 |
| Celecoxib | Celecoxib | 114 | 48 |
| Doxycycline Hyclate | Doxycycline Hyclate | 114 | 99 |
| Azithromycin | Azithromycin | 112 | 102 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 112 | 34 |
| Metformin Hcl Er | Metformin Hcl | 111 | 32 |
| Citalopram Hbr | Citalopram Hydrobromide | 110 | 31 |
| Hydralazine Hcl | Hydralazine Hcl | 110 | 36 |
| Ondansetron Odt | Ondansetron | 103 | 56 |
| Farxiga | Dapagliflozin Propanediol | 101 | 23 |
| Jardiance | Empagliflozin | 100 | 31 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 97 | 25 |
| Glimepiride | Glimepiride | 95 | 27 |
| Tresiba Flextouch U-100 | Insulin Degludec | 94 | 27 |
| Ramipril | Ramipril | 89 | 19 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 89 | 28 |
| Ibuprofen | Ibuprofen | 86 | 39 |
| Mirtazapine | Mirtazapine | 82 | 23 |
| Cefuroxime | Cefuroxime Axetil | 81 | 58 |
| Zolpidem Tartrate | Zolpidem Tartrate | 80 | 31 |
| Cefdinir | Cefdinir | 78 | 68 |
| Clonidine Hcl | Clonidine Hcl | 78 | 18 |
| Donepezil Hcl | Donepezil Hcl | 77 | 24 |
| Eliquis | Apixaban | 77 | 19 |
| Memantine Hcl | Memantine Hcl | 76 | 20 |
| Alprazolam | Alprazolam | 74 | 16 |
| Fluoxetine Hcl | Fluoxetine Hcl | 72 | 25 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 71 | 19 |
| Finasteride | Finasteride | 70 | 22 |
| Clonazepam | Clonazepam | 68 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 68 | 36 |
| Pregabalin | Pregabalin | 68 | 26 |
| Famotidine | Famotidine | 67 | 25 |
| Lorazepam | Lorazepam | 65 | 17 |
| Irbesartan | Irbesartan | 63 | 16 |
| Methylprednisolone | Methylprednisolone | 63 | 55 |
| Mounjaro | Tirzepatide | 61 | suppressed |
| Atenolol | Atenolol | 60 | 17 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 60 | 16 |
| Sucralfate | Sucralfate | 60 | 23 |
| Fenofibrate | Fenofibrate | 59 | 17 |
| Nebivolol Hcl | Nebivolol Hcl | 59 | 17 |
| Trulicity | Dulaglutide | 59 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 57 | 16 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 56 | 34 |
| Fluconazole | Fluconazole | 55 | 32 |
| Spironolactone | Spironolactone | 54 | 21 |
| Warfarin Sodium | Warfarin Sodium | 54 | 13 |
| Alendronate Sodium | Alendronate Sodium | 53 | 15 |
| Benazepril Hcl | Benazepril Hcl | 53 | 16 |
| Valacyclovir | Valacyclovir Hcl | 53 | 30 |
| Tresiba Flextouch U-200 | Insulin Degludec | 52 | 15 |
| Xarelto | Rivaroxaban | 50 | suppressed |
| Lansoprazole | Lansoprazole | 49 | 14 |
| Januvia | Sitagliptin Phosphate | 48 | 11 |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 46 | 18 |
| Quetiapine Fumarate | Quetiapine Fumarate | 46 | 12 |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 45 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 45 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 44 | 15 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 44 | 11 |
| Oxybutynin Chloride | Oxybutynin Chloride | 43 | 17 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 42 | 35 |
| Colchicine | Colchicine | 42 | 23 |
| Estradiol | Estradiol | 41 | 12 |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 41 | 32 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 39 | 28 |
| Nystatin | Nystatin | 39 | 17 |
| Tramadol Hcl | Tramadol Hcl | 39 | 28 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 39 | suppressed |
| Diazepam | Diazepam | 38 | 11 |
| Doxepin Hcl | Doxepin Hcl | 38 | 20 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 37 | 18 |
| Diclofenac Sodium | Diclofenac Sodium | 35 | 18 |
| Linzess | Linaclotide | 35 | 15 |
| Methocarbamol | Methocarbamol | 35 | suppressed |
| Myrbetriq | Mirabegron | 35 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 34 | 27 |
| Indapamide | Indapamide | 33 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 33 | 11 |
| Propranolol Hcl | Propranolol Hcl | 33 | 11 |
| Baclofen | Baclofen | 32 | suppressed |
| Prednisone | Prednisone | 32 | 18 |
| Symbicort | Budesonide/Formoterol Fumarate | 31 | suppressed |
| Mupirocin | Mupirocin | 30 | 26 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 30 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 29 | suppressed |
| Naproxen | Naproxen | 29 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 28 | suppressed |
| Amoxicillin | Amoxicillin | 25 | 22 |
| Telmisartan | Telmisartan | 25 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 24 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 24 | 14 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 24 | suppressed |
| Droplet Pen Needle | Pen Needle, Diabetic | 23 | suppressed |
| Ibu | Ibuprofen | 23 | 11 |
| Acyclovir | Acyclovir | 22 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 22 | suppressed |
| Lovastatin | Lovastatin | 22 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 22 | 11 |
| Paxlovid | Nirmatrelvir/Ritonavir | 22 | 22 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 21 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 21 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 20 | suppressed |
| Ketoconazole | Ketoconazole | 20 | 14 |
| Terazosin Hcl | Terazosin Hcl | 20 | suppressed |
| Cephalexin | Cephalexin | 19 | 13 |
| Glipizide Er | Glipizide | 19 | suppressed |
| Nifedipine Er | Nifedipine | 19 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 19 | suppressed |
| Telmisartan-Hydrochlorothiazid | Telmisartan/Hydrochlorothiazid | 19 | suppressed |
| Victoza 3-Pak | Liraglutide | 19 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 18 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 18 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 18 | suppressed |
| Primidone | Primidone | 18 | suppressed |
| Wegovy | Semaglutide | 18 | suppressed |
| Betamethasone Valerate | Betamethasone Valerate | 17 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 17 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 17 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 17 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 17 | suppressed |
| Trandolapril | Trandolapril | 17 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 16 | suppressed |
| Hydrocortisone | Hydrocortisone | 16 | suppressed |
| Klor-Con 10 | Potassium Chloride | 16 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 16 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 15 | suppressed |
| Temazepam | Temazepam | 15 | suppressed |
| Boostrix Tdap | Diphth,pertuss(Acell),tet Vac | 14 | 14 |
| Calcitriol | Calcitriol | 14 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 14 | suppressed |
| Methylphenidate Hcl | Methylphenidate Hcl | 14 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 14 | suppressed |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 13 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 13 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 13 | 11 |
| Ipratropium Bromide | Ipratropium Bromide | 13 | suppressed |
| Novolog Flexpen | Insulin Aspart | 13 | suppressed |
| Oxazepam | Oxazepam | 13 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 13 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 12 | suppressed |
| Lidocaine | Lidocaine | 12 | suppressed |
| Brilinta | Ticagrelor | 11 | suppressed |
| Clonidine | Clonidine | 11 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 11 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 11 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 11 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 11 | suppressed |
| Levofloxacin | Levofloxacin | 11 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 11 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 11 | suppressed |
| Vascepa | Icosapent Ethyl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $783.29 · 39 records | Abbott Laboratories | AIRSUPRA, AREXVY, BREZTRI, Cologuard Collection Kit, EVENITY, FREESTYLE LIBRE, GVOKE HYPOPEN, KISUNLA, Korlym, LEQVIO, MOUNJARO, NURTEC ODT, OTEZLA, Ozempic, PROLIA, QULIPTA, REPATHA, REXULTI, Rybelsus, SHINGRIX, TRELEGY ELLIPTA, UBRELVY, ZAVZPRET, ZEPBOUND | 14 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Mounjaro play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error